Globus Medical

GMED on NYSE. Surgical & medical instruments & apparatus. Market value $10.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
7.4%high

For every $100 of what the whole company costs, it produced $7.36 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 80 of 100. Price score: 78 of 100. Our list needs 70 on quality and 60 on price.

$76.43 a share, 35% above its 1-year low

Over the past year the price has ranged from $56.50 to $101.40.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.2
0.1
0.2
0.4
0.6
0.8
2021202220232024202512 monthsto Jun '26
Revenue
$958m$1.0bn$1.6bn$2.5bn$2.9bn
Operating margin
17.9%22.3%8.5%6.6%16.3%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.10bn0.14bn0.14bn0.13bn0.13bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)7 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 30.1% a year
  • Buying back its own sharesNo, 34% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $790 million last quarter, up 6% on a year ago.
  • Profit: $152 million, down 25% on a year ago.
  • It keeps 20 cents of each $1 of sales as operating profit, up from 11 cents a year earlier.
  • Spare cash over the past 12 months: $756 million, up from $527 million.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$626m
December 2024$657m
March 2025$598m
June 2025$745m
September 2025$769m
December 2025$826m
March 2026$760m
June 2026$790m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$52m
December 2024$27m
March 2025$75m
June 2025$203m
September 2025$119m
December 2025$141m
March 2026$124m
June 2026$152m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
24 February 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

6 long-term investors we follow own it, up from 5 last quarter. 597 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 7 sold $18m, $7m of it under preset trading plans.

  • TOBIN JAMES R
    Director
    Sold
    Date
    15 September 2026
    Shares
    30,000
    Price
    $74.58
    Value
    $2m
  • ZARRILLI STEPHEN T
    Director
    Sold
    Date
    18 August 2026
    Shares
    25,000
    Price
    $87.04
    Value
    $2m
  • Davidar David D
    Director
    Sold
    Date
    5 June 2026
    Shares
    25,000
    Price
    $80.76
    Value
    $2m
  • Huller Kelly
    EVP, GC, Corporate Secretary
    Sold
    under a preset trading plan
    Date
    25 February 2026
    Shares
    20,000
    Price
    $94.50
    Value
    $2m
  • Huller Kelly
    EVP, GC, Corporate Secretary
    Sold
    under a preset trading plan
    Date
    12 February 2026
    Shares
    10,000
    Price
    $87.67
    Value
    $876,700
  • Kline Kyle
    Senior Vice President, CFO
    Sold
    under a preset trading plan
    Date
    8 January 2026
    Shares
    3,594
    Price
    $101.10
    Value
    $363,353
  • Norwalk Leslie V
    Director
    Sold
    under a preset trading plan
    Date
    8 January 2026
    Shares
    2,000
    Price
    $101.10
    Value
    $202,200
  • Norwalk Leslie V
    Director
    Sold
    under a preset trading plan
    Date
    12 December 2025
    Shares
    4,000
    Price
    $88.85
    Value
    $355,400
  • Kline Kyle
    Senior Vice President, CFO
    Sold
    under a preset trading plan
    Date
    1 December 2025
    Shares
    18,542
    Price
    $90.00
    Value
    $2m
  • Huller Kelly
    SVP, GC, Corporate Secretary
    Sold
    under a preset trading plan
    Date
    25 November 2025
    Shares
    7,500
    Price
    $90.00
    Value
    $675,000

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 24 Feb 2026, plus the 10-Q filed 6 Aug 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.

    Could happen
    Additionally, our Bylaws provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provisions may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice-of-forum provisions contained in the Bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions. The exclusive forum provisions in the Bylaws will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the federal securities laws including the Exchange Act or the Securities Act, as amended, or the respective rules and regulations promulgated thereunder.
    Read more
  • The Company’s Bylaws provide, to the fullest extent permitted by law, that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between the Company and its stockholders, which could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.

    Could happen
    Our Bylaws provide, to the fullest extent permitted by law, that unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee of the Company to the Company or the Company’s stockholders; (iii) any action asserting a claim against the corporation or any director or officer or other employee of the Company arising pursuant to any provision of the General Corporation Law of Delaware or the certificate of incorporation or the Bylaws (as either may be amended from time to time); and (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine, in each case, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court of the District of Delaware).
    Read more
  • Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel, and if we do not successfully manage the transition associated with the resignation of our former chief executive officer and the appointment of our new chief executive officer, it could have an adverse impact on our business.

    Could happen
    Additionally, during 2025, Daniel Scavilla, our former Chief Executive Officer, resigned from the Company and was replaced by Mr. Pfeil, who had previously served as the Chief Operating Officer and Chief Financial Officer. Although the Board is confident in the leadership of Mr. Pfeil, leadership transitions can be inherently difficult to manage, and an inadequate transition may cause disruption to the Company’s business. Accordingly, if we do not successfully manage the transition, it could have an adverse impact on our business.
    Read more
  • Tariff policies and potential countermeasures have and may continue to increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.

    In 2025, the U.S. enacted the imposition of widespread and substantial tariffs on imports, which resulted in the imposition of reciprocal or retaliatory tariffs and continued tariff volatility and uncertainty. The tariffs enacted by the U.S. included a universal baseline tariff of 10%, plus an additional country-specific tariff for select countries. On February 20, 2026, the U.S. Supreme Court held that the U.S. administration’s imposition of many such tariffs was unlawful, striking down the 10% tariff, as well as the higher tariffs imposed on certain U.S. partners, including, among others, Canada, Mexico, and China. The U.S. Supreme Court’s ruling did not affect all of the recently imposed tariffs. Nor does it prohibit the imposition of future tariffs through alternative trade authorities available to the U.S. administration. Accordingly, uncertainty with respect to the tariffs remains ongoing, and we are unable to predict what additional actions, if any, may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, which products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by any other countries in retaliation, or the impact, if any, that any such policy changes could have on our business. The potential resultant impact of the imposition of these or any other new or increased tariffs on import markets has and could further have an adverse effect on Globus’ results of operations, cash flow and financial condition.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.